Effects of e-Cigarettes on Perceptions and Behavior - Substudy 1

July 7, 2023 updated by: Adam Leventhal, University of Southern California
This project will assess the ways in which e-cigarette product diversity impacts the user experience to inform potential regulations by identifying product characteristics that may: (1) put young adults at risk for tobacco product use; and (2) facilitate adult smokers switching to e-cigarettes. There are three primary objectives to the study: (1) Determine which dimensions of e-cigarette product diversity differentially affect product appeal in the overall population of tobacco product users as well as affect product appeal across young adult e-cigarette users and middle-age/older adult smokers; (2) Determine which dimensions of e-cigarette product diversity differentially affect product appeal in the overall population of tobacco product users as well as affect abuse liability in young adult e-cigarette users and the ability to resist smoking in adult smokers; (3) Determine the affect of product characteristics on e-cigarette nicotine delivery profile. For this substudy, young adult vapers (N=100) and adult smokers (N=100) will attend one laboratory session in which they will self-administer e-cigarette products varied according to within-subject e-cigarette factors (e.g., flavor, nicotine formulation).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
124

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90033
        • University of Southern California

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Vapers/E-cigarette Users

  • E-cigarette/vaping device use at least three days per week for at least 2 months
  • Regular use of e-cigarettes/vaping devices containing nicotine

Cigarette Smokers

  • Daily cigarette smoking for at least two years
  • Currently smoke at least four cigarettes per day
  • Interested in trying an e-cigarette or current use of an e-cigarette

Exclusion Criteria:

Vapers/E-cigarette Users

  • Pregnant or breastfeeding
  • Desire to cut down on use of e-cigarette/vaping device

Cigarette Smokers

  • Pregnant or breastfeeding
  • Current daily use of other combustible tobacco products (such as cigars)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: E-cigarette e-liquid 1
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 2
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 3
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 4
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 5
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 6
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 7
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 8
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 9
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 10
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 11
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 12
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 13
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 14
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 15
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 16
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 17
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 18
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 19
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.
Experimental: E-cigarette e-liquid 20
Participants will self-administer an e-cigarette e-liquid.
Drug: E-cigarette e-liquid
Participants will self-administer an experimenter-provided e-cigarette.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Subjective Appeal
Time Frame: 1 hour
Self-report measures of product appeal will be completed following e-cigarette self-administration.
1 hour
Sensory Appeal
Time Frame: 1 hour
Self-report measures of product appeal will be completed following e-cigarette self-administration.
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Southern California

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Adam M Leventhal, PhD, University of Southern California

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 18, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 18, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 22, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 11, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 7, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HS-18-00839 Substudy 1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings